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Abstract
Purpose: This study examined the population-based use and outcomes of brain radiotherapy (BRT) for brain
metastases (BM) from breast cancer with a focus on repeat BRT in the trastuzumab era.
Methods and materials: All women with breast cancer diagnosed from 2000-2007 and treated with BRT were
retrospectively identified from a provincial database.
Results: A total of 441 women with BM from breast cancer were identified. The median age was 55 years and 40%
(176/441) had human epidermal growth factor receptor 2 (HER2) positive disease. The median survival (MS) from
the initial BRT for all 441 women was 4.5 months. The MS by Radiation Therapy Oncology Group Recursive
Partitioning Analysis (RPA) class was: 1 (14.5 months), 2 (6.4 months) and 3 (1.8 months). For the 37 cases receiving
repeat BRT, 27% (10/37) had stereotactic radiosurgery (SRS) and 70% (26/37) had HER2 positive disease, of which,
81% (21/26) received trastuzumab in the metastatic setting. For repeat BRT, the median survival by RPA class was: 1
(9.8 months), 2 (7.4 months) and 3 (2.0 months). For RPA class 1 and 2, the one-year overall survival (OS) was 45%.
Conclusion: The proportion of cases with HER2 positive disease was increased at repeat BRT compared to initial
BRT. RPA class 1 and 2 patients should be considered for repeat BRT.
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Introduction
Breast cancer is the second most common cause of BM
and accounts for 5% to 15% of patients with BM [1,2].
Presenting symptoms include headaches, focal weak-
nesses, mental disturbances, seizures, speech difficulties,
visual disturbances; any of which can impact on a
patient’s quality of life and length of survival [3]. His-
torically, median survival in patients with metastatic dis-
ease to the brain has been reported to be 3 to 4 months
[4]. Younger age, presence of visceral metastases, nega-
tive estrogen receptor (ER) status and larger primary
tumour size have all been associated with an increased
risk of cerebral metastases [2]. In addition, the epider-
mal growth factor receptor 2 (HER2) has been shown to
be a significant predictive and prognostic factor for the
development of BM [2]. HER2 over-expression has been
reported in 20%-25% of human breast cancers and is
associated with a reduced overall and disease-free survi-
val [2,5]. In an analysis of patients with invasive breast
cancer referred to the British Columbia Cancer Agency
(BCCA) in 2009, HER2 overexpression was identified in
16% of cases.
Studies demonstrated improved OS and progression-
free survival with the use of trastuzumab in combination
with chemotherapy in the setting of metastatic breast
cancer in 1998 [2,6]. Improvements in disease-free survi-
val and OS were demonstrated with trastuzumab adju-
vant therapy in 2005 [7]. When the HER2 receptor is
amplified in patients with breast cancer, the cancer cells
tend to spread to the brain [8,9]. Improvement in the
control of visceral metastasis with trastuzumab in
patients with HER2 overexpression has led to longer
patient survival, which increases the predilection of
developing clinically apparent BM [9].
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is the most common local treatment for BM, followed
by other treatment modalities including surgery and
SRS in selected cases. Many patients with a good
response to initial treatment of their BM will relapse in
the brain, especially when the rest of their systemic dis-
ease is well controlled. Treatment options for recurrent
cranial metastatic disease include repeat surgery, WBRT,
SRS, chemotherapy and/or comfort care [8].
This is a report of a population-based study of the
clinical characteristics, prognostic variables, and out-
comes in patients who were treated with BRT for meta-
static breast cancer in the modern era (i.e. when
trastuzumab, SRS, and craniotomy for metastatic disease
were available), with a special emphasis on outcomes
after repeat BRT.
Methods and materials
The BCCA provides all radiation therapy in the province
of BC for a population of approximately 4.5 million. The
BC Cancer Registry contains demographic data on all
incident cancers, and captures date and cause of death
data from death certificates. HER2 status has been
tested in patients with breast cancer in BC since 1999,
and trastuzumab became available for patients with
metastatic breast cancer outside of a trial setting in BC
in February 1999. SRS for patients with BM has been
available in the province since 1998. Craniotomy for
patients with BM has been practiced for decades in the
province in selected cases, but became more widely
practiced during the 1990’s after the randomized trial by
Patchell et al [10].
Using unique BCCA patient identifier codes, all
women with breast cancer diagnosed from January 2000
to December 2007 who were treated with BRT for BM
from breast cancer were identified. Among those, the
patients treated with more than one course of BRT were
also identified. Patients who had leptomeningeal disease
(n = 7), metastatic disease to the skull (without parench-
ymal brain mets) (n = 55), prophylactic cranial irradia-
tion in a clinical trial (n = 4), and male patients (n = 1)
were excluded. This left 441 patients who were the sub-
jects of the initial BRT cohort. Among those, 37 patients
received a second course of BRT, three or more months
after the initial course as whole brain, partial brain or
SRS.
The charts of the 441 patients were reviewed and the
following information was collected: age, initial stage of
breast cancer, grade, hormone receptor status, HER2
status, chemotherapy use on or after the date of first
BM, hormonal therapy on or after the date of first BM,
trastuzumab use at any point and within 90 days of
diagnosis of BM. In addition, control of primary, pre-
sence of extracranial metastases and number of brain
lesions were abstracted at time of initial BRT and prior
to repeat BRT. Karnofsky performance status (KPS) (≥
70 or < 70) and the Eastern Cooperative Oncology
Group (ECOG) performance status classification were
identified retrospectively at initial diagnosis of BM and
before repeat BRT from a description of the patient’s
clinical status in the chart records. A Radiation Therapy
Oncology Group Recursive Partitioning Analysis (RPA)
risk group [11] was determined for each patient prior to
initial BRT and prior to repeat BRT. The RPA risk
group used four factors: age, KPS, primary controlled/
uncontrolled and extracranial metastases. Factors were
inputted by the investigator for each patient and a RPA
class was assigned. Patients with a KPS of < 70 were
identified as class 3, patients with KPS ≥ 70, with con-
trolled primary disease, age < 65 years and absence of
extracranial metastases were identified as class 1, and all
other patients as class 2 [11].
The clinical response to initial BRT and repeat BRT at
3 to 6 months from BRT was determined from the med-
ical records. The clinical response was classified as:
complete response-disappearance of neurological symp-
toms; partial response-alleviation of neurological symp-
toms; stable disease-no change in neurological
symptoms; progressive disease-deterioration of neurolo-
gical symptoms as described by Sadikov et al.[ 1 2 ] .T h e
radiological response to radiation therapy at 3-6 months
after initial and repeat BRT was abstracted from the
radiologist’s report of a post-BRT CT or MRI scan and
classified as follows: complete response-disappearance of
brain lesions; tumour reduction-decrease in size of brain
lesions; stable disease-no change in size of brain lesions;
p r o g r e s s i v ed i s e a s e - i n c r e a s ei ns i z ea n d / o rn e wb r a i n
lesions. Cases with missing information were classified
as non -evaluable.
All analyses were conducted using Statistical Package
for Social Sciences, version 14.0 (SPSS, Chicago, IL). OS
was assessed using the Kaplan-Meier method and com-
pared using the log-rank test. The survival time was
measured from the date of starting initial BRT to the
date of death or last follow-up and from the date of
starting repeat BRT to the date of death or last follow-
up. Patient characteristics were presented as a descrip-
tive frequency for categorical variables. The association
between each of the patient characteristics and out-
comes was evaluated with univariate and multivariable
analyses using a Cox regression model. This study was
approved by the Research Ethics Board of the University
of BC.
Results
Initial brain irradiation
Table 1 demonstrates the patient characteristics for all
441 women diagnosed with breast cancer and treated
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those who received a second course of BRT. The med-
ian age for all 441 women was 55 years and 78% of
patients were younger than 65 years (Table 1). There
were 113 (26%) woman who had stage 4 disease at the
time of initial diagnosis of their breast cancer. One hun-
dred seventy six patients were HER2 positive (40%).
Most women had grade 3 disease (n = 315, 71%) and
had a negative ER status (n = 249, 56%). At the time of
their BM diagnosis, the majority of patients (61%) had a
KPS of 70 or higher. Most of the patients, 251 (57%),
had multiple BM, and 344 (78%) had extracranial dis-
ease. Eighty-seven patients (20%) had a craniotomy. The
RPA class of the patients was: 1 (55 patients), 2 (219
patients) and 3 (167 patients). One hundred and thirty
six patients (74% of all HER2 positive patients) were
treated with trastuzumab on or after the date of their
first BM.
The two most common prescriptions for the initial
WBRT were 20 Gy in 5 fractions (64%) and 30 Gy in 10
fractions (24%). WBRT was followed by a SRS boost in
4% of cases. As shown in Figure 1, the MS for all 441
subjects was 4.5 months and 26% were alive at 1 year.
MS was longer (7.0 months) for the 176 subjects (40%)
who had HER2 positive disease compared to those with
HER2 negative disease (3.8 months, p < 0.0001) (Figure
2). The survival by RPA class was: 1 (14.5 months), 2
(6.4 months) and 3 (1.8 months) (p < 0.0001).
On univariate analysis, RPA class at diagnosis of BM
(p < 0.001), SRS boost at initial BM (p < 0.001), use of
craniotomy (p < 0.001), the presence of a solitary brain
lesion (p < 0.001), HER2 overexpression (p < 0.001),
chemotherapy use (p < 0.001), hormonal therapy use (p
< 0.001) and trastuzumab therapy use (p < 0.001) at BM
were all found to be favourable prognostic factors for
survival (Table 2). On multivariable analysis, the only
significant prognostic factors for survival were the RPA
class (p < 0.001), SRS boost use (p = 0.002), craniotomy
use (p < 0.001), HER2 status (p = 0.015), chemotherapy
use (p < 0.001) and hormonal therapy use (p < 0.001)
(Table 2).
Table 1 Patient characteristics prior to initial brain
irradiation
Patient Characteristics n = 441 n=37
Age (years)
Median 55 48
Grade, primary tumor
1 13 (3%) 1 (3%)
2 106 (24%) 13 (35%)
3 315 (71%) 22 (59%)
Unknown 7(2%) 1 (3%)
Hormone receptor status, primary tumor
ER+ 180 (41%) 14 (38%)
ER- 249 (56%) 22 (60%)
Unknown 12 (3%) 1 (2%)
HER2 status, primary tumor
Positive 176 (40%) 26 (70%)
Negative 212 (48%) 7 (19%)
Unknown 53 (12%) 4 (11%)
KPS at first BM
< 70 170 (38%) 10 (27%)
≥ 70 271 (61%) 27 (73%)
ECOG at first BM
0-1 109 (25%) 21 (57%)
2 186 (42%) 13 (35%)
3-4 146 (33%) 3 (8%)
Number of lesions
1-3 190 (43%) 21 (57%)
> 3 251 (57%) 16 (43%)
Primary status
Controlled 305 (69%) 28 (76%)
Uncontrolled 135 (31%) 9 (24%)
Extracranial disease
Brain only 97 (22%) 19 (51%)
Bone + brain 76 (17%) 6 (16%)
Visceral + brain 245 (56%) 12 (32%)
Other 23 (5%) 0 (0%)
RPA at first BM
1 55 (12%) 11 (30%)
2 219 (50%) 16 (43%)
3 167 (38%) 10 (27%)
Hormonal therapy at BM*
Yes 100 (23%) 14 (38%)
No 341 (77%) 23 (62%)
Chemotherapy at BM*
Yes 194 (44%) 29 (78%)
No 242 (55%) 8 (22%)
Trastuzumab at BM*
Yes 136 (31%) 21 (57%)
No 305 (69%) 16 (43%)
Trastuzumab†
Yes 157 (36%) 25 (67%)
No 284 (64%) 12 (32%)
Table 1 Patient characteristics prior to initial brain irra-
diation (Continued)
Craniotomy
Yes 87 (20%) 16 (43%)
No 354 (80%) 21 (57%)
* Refers to treatments given on or after the date of first brain metastases.
†Trastuzumab use at any point including those within 90 days of brain
metastases.
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor
receptor 2, BM = brain metastasis, KPS = karnofsky performance status, ECOG
= eastern cooperative oncology group, RPA = recursive partitioning analysis
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the clinical and radiological response at 3 to 6 months
after BRT in 49% (n = 218) and 75% (n = 111) of
patients. A clinical improvement following initial BRT
was reported in 94 patients (43%), 67 patients (31%) did
not experience changes in their neurological symptoms
and 57 patients (26%) deteriorated following irradiation.
With respect to the radiological response, 62 patients
(56%) had either complete resolution or reduction in the
size of their lesions on imaging, 22 (20%) had stable dis-
ease and 27 patients (24%) had progression of their
brain lesions on imaging.
Brain re-irradiation
Table 3 demonstrates the characteristics for the 37
patients treated with repeat BRT using WBRT, partial
BRT or SRS. The median age was 48 years. The med-
i a nt i m ei n t e r v a lf r o mt h ee n do ft h ef i r s tc o u r s eo f
BRT to repeat BRT was 29 months [4-58 months].
Most patients, 73% (27/37), had a KPS of 70 or greater
prior to re-irradiation. In addition, 59% (22/37) of
patients had multiple BM prior to re-irradiation, 59%
(22/37) of patients had their primary breast disease
controlled and 73% (27/37) of patients had extracranial
disease. Among the patients who received re-irradia-
tion, 70% (26/37) had HER2 positive disease, 57% (21/
37) received trastuzumab on or after the date of the
first BM and only 16% (6/37) of patients were on tras-
tuzumab on or after progression or recurrence of the
BM. All patients received a first course of WBRT for
metastatic disease. The most common initial prescrip-
t i o n sw e r e2 0G yi n5f r a c t i o n s( n=2 1 )a n d3 0G yi n
10 fractions (n = 14). Retreatment schemes were more
variable, and included 20 Gy in 5 fractions (n = 11), 20
Gy in 10 fractions (n = 5) and 15 Gy in 5 fractions (n
= 5). Ten patients (27%) received salvage SRS doses
between 15 and 30 Gy in a single fraction. Seventeen
patients (46%) were treated with WBRT and 12
patients (32%) received partial BRT as part of their
second course of RT.
A ss h o w ni nF i g u r e3 ,t h eM Sa f t e rr e p e a tB R Tw a s
6.9 months and 14% (n = 5) were alive at 3 years. Of
the re-irradiated patients with HER2 positive disease,
the MS was 7.5 months compared to 6.9 months for the
patients with HER2 negative disease (p = 0.67) (Figure
4). Among patients treated with salvage SRS, 30% (3/10)
lived beyond 3 years. The strongest prognostic factors of
patients treated with repeat BRT were the RPA class (p
< 0.001), number of brain lesions at re-irradiation (p =
0.001) and tumour grade (p < 0.001) (Table 4). For
patients with favourable prognostic features (RPA class
1) at the time of re-irradiation, the MS was 9.8 months,
compared to 7.4 months for RPA class 2 and 2 months
for RPA class 3 (Figure 5). The 1-year OS was 45% for
RPA class 1 and 2, compared to 0% for RPA class 3 (p
< 0.001). Following re-irradiation, 41% remained symp-
tomatically stable, 14% had a partial clinical response
and 19% had progressive disease at 3 to 6 months.
 
Overall survival after initial brain irradiation by HER2 status.
Figure 2 Overall survival after initial brain irradiation by HER2
status, 441 patients.
Overall survival after initial brain irradiation. 
Figure 1 Overall survival after initial brain irradiation, 441
patients.
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26% of the repeat BRT patients.
Discussion
Brain irradiation has proven useful in the treatment of
BM from breast cancer [3]. Some oncologists have been
reluctant to consider repeat BRT due to uncertainty
about the degree of benefit and concern about the risk
of severe toxicities. In recent years, many studies have
reported a higher risk of central nervous system (CNS)
metastases in HER2 positive patients with metastatic
breast cancer [9]. The better control of extracranial dis-
ease reported in HER2 positive patients treated with
trastuzumab was likely the cause of the longer survival
of these CNS metastatic patients, and more cases with
indications for repeat BRT. To our knowledge, this is
the first population-based study describing the patterns
of repeat BRT in patients with metastatic breast cancer
treated in the current era. The results of population-
based studies, such as this one, are more generalizable
than results of randomized trials, or from single institu-
tion, tertiary referral centres.
Historically, the MS of patients with breast cancer
metastatic to the brain has been poor, ranging from 3
months to 5 months [3]. In the current series of 441
patients treated with initial WBRT, the OS was 7.0
months among HER2 positive patients, with 40% of
patients surviving more than 12 months. The MS for
the HER2 negative patients was still only 3.8 months,
which was similar to that previously reported. On a
multivariable analysis, the significant prognostic factors
were RPA class, SRS use, craniotomy use, HER2 status,
chemotherapy use and hormonal therapy use. Several
prognostic factors had been suggested in the literature,
in patients treated with initial WBRT. The RTOG 79-16
study, identified KPS of 70-100, an absent/controlled
primary tumour, age < 60 years, and metastatic spread
limited to the brain as favourable prognostic factors for
survival [13]. The prognostic value of these factors was
confirmed in the current series. Patients with favourable
prognostic factors (RPA class 1) had a MS of 14.5
months whereas patients with unfavourable prognostic
features (RPA class 3) had a MS of 1.8 months, which
was similar to the MS reported by Gaspar et al.( 7 . 1
Table 2 Univariate and multivariate analysis of potential prognostic factors at initial brain irradiation
Univariable Analysis Multivariable Analysis
Characteristics HR (95% CI) p value HR (95% CI) p value
RPA at diagnosis of BM
1 1 [Reference] 1 [Reference]
2 1.92 (1.30-2.82) < 0.001 1.55 (1.00-2.40) 0.05
3 5.23 (3.50-7.80) < 0.001 4.24 (2.66-6.73) < 0.001
SRS boost at initial BM
Yes 1 [Reference] 1 [Reference]
No 3.05 (1.71-5.44) < 0.001 2.94 (1.51-5.73) 0.002
Craniotomy
Yes 1 [Reference] 1 [Reference]
No 2.87 (2.15-3.84) < 0.001 2.70 (1.89-3.85) < 0.001
Number of lesions
1 1 [Reference] 1 [Reference]
2-3 1.31 (0.91-1.89) 0.139 1.19 (0.82-1.72) 0.36
> 3 2.18 (1.66-2.88) < 0.001 1.02 (0.78-1.34) 0.88
HER2 status
Positive 1 [Reference] 1 [Reference]
Negative and Equivocal 1.74 (1.39-2.18) < 0.001 1.55 (1.09-2.20) 0.015
Chemotherapy at BM
Yes 1 [Reference] 1 [Reference]
No 2.26 (1.81-2.84) < 0.001 1.81 (1.41-2.33) < 0.001
Hormonal therapy at BM
Yes 1 [Reference] 1 [Reference]
No 1.64 < 0.001 2.22 (1.66-2.97) < 0.001
Trastuzumab at initial BM
Yes 1 [Reference] 1 [Reference]
No 1.74 (1.37-2.20) < 0.001 1.37 (0.94-2.01) 0.100
Abbreviations: RPA = recursive partitioning analysis, SRS = stereotactic radiosurgery, HER2 = human epidermal growth factor receptor 2, BM = brain metastasis
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Page 5 of 8months for RPA class 1, and 2.3 months for the RPA
class 3 patients) [11].
With respect to the re-irradiation cohort, the MS was
6.9 months from the start date of the second course of
BRT. Historic series from other institutions have
described a MS after repeat BRT ranging from 2.0 to 4.7
months for most common sites, including lung and
breast cancers [12,14-18]. Most of these retrospective
studies pertain to the pre-trastuzumab era, when brain
re-irradiation was less frequent and systemic therapy
not comparable to the current era [12,14-18]. The lar-
gest series to date, reported a MS of 4.0 months and on
univariate analysis, absence of extracranial metastasis,
solitary BM and a retreatment dose > 20 Gy were asso-
ciated with improved survival [18].
The current study identified a subset of patients who
benefited from repeat BRT in terms of survival. Patients
with favourable prognostic features (RPA class 1) had a
MS of 9.8 months after their second course of BRT.
Another finding of these series, is the high proportion
of HER2 overexpression in patients with brain involve-
ment, as has been described by other authors [1,2,9].
Consequently, the need for local control of intracranial
lesions is required, especially since for some of these
patients, the probability of survival is associated with
more aggressive treatment to the brain. From the
BCCA’s Breast Cancer Outcomes Unit database in 2009,
16% of all invasive breast cancers with known HER2 sta-
tus referred to the BCCA were HER2 positive at the
time of initial diagnosis, and of those with metastatic
disease at the time of referral, 28% were HER2 positive.
As described in the current study, 40% of those with
initial BRT were HER2 positive, and of those with repeat
BRT, 70% were HER2 positive. This reflects the predi-
lection of HER2 positive disease for brain involvement
particularly with better systemic control outside the
brain. However, it is possible that with longer follow-up,
we would have seen more HER2 negative disease recur-
ring in the brain, and the high proportion of HER2 posi-
tive disease may reflect the aggressive early relapse in
the brain in addition to a predilection for brain
involvement.
Table 3 Patient characteristics of 37 cases prior to re-
irradiation
Patient Characteristics prior to re-BRT n = 37
Age (years)
Median 48
KPS
< 70 10 (27%)
≥ 70 27 (73%)
ECOG
0-1 12 (32%)
2 20 (54%)
3-4 5 (13%)
Number of lesions
1-3 15 (40%)
> 3 22 (59%)
Primary status
Controlled 22 (59%)
Uncontrolled 15 (40%)
Extracranial disease
Brain only 10 (27%)
Bone 6 (16%)
Visceral 19 (51%)
Other 2 (5%)
RPA at re-BRT
1 12 (32%)
2 10 (27%)
3 15 (40%)
Chemotherapy at BM*
Yes 19 (51%)
No 18 (49%)
Trastuzumab at BM*
Yes 6 (16%)
No 31 (84%)
* Refers to treatments given on or after the date of brain re-irradiation.
Abbreviations: re-BRT = re-irradiation, RPA = recursive partitioning analysis, KPS
= karnofsky performance status, ECOG = eastern cooperative oncology group
performance status, BM = brain metastasis
Overall survival after repeat brain irradiation. 
Figure 3 Overall survival after repeat brain irradiation, 37
patients.
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data, such as response rates and performance status
were abstracted, and in some cases coded, retrospec-
tively. This limits the strength of the response rates
findings, and decreases the discrimination of our per-
formance status categories. The beneficial effects of
steroids could not be separated from the effect of
irradiation due to limitations in the documentation.
Data on toxicity was not abstracted due to the limita-
tions of a retrospective design. The re-irradiation
cohort, while among the largest published series of
patients with breast cancer receiving repeat BRT, still
had a limited number of patients who may have been
highly selected from patients relapsing in the brain
and this may explain the somewhat favourable survi-
val results. Given the small re-irradiation cohort, a
multivariate analysis of prognostic variables was not
feasible.
Additionally, the RPA prognostic index by Gaspar et
al. does not take into account the primary site as a
parameter and the number of brain lesions. The
RTOG 9508 trial showed that the number of BM was
prognostic when comparing one to two or three BM
[19]. A survival benefit was demonstrated for patients
with a single brain lesion when treated with WBRT
and SRS versus WBRT alone, whereas no survival ben-
efit was shown for patients with multiple BM [19].
The significance of diagnosis-specific prognostic fac-
tors and indexes has been demonstrated by Sperduto
et al. through the Graded Prognostic Assessment
(GPA) [20]. The GPA uses four criteria: age, KPS,
number of BM and presence of extracranial metastases
to compute a score from 0.0 to 4.0, with the maxi-
mum score of 4.0 having the best prognosis [20]. In
patients with breast cancer, the only significant prog-
nostic factor found on a multivariate analysis was the
K P S[ 2 0 ] .T h ec u r r e n ts t u d yd i dn o tu s et h eG P A
index, because the KPS was often not documented
explicitly in the chart.
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Overall survival after repeat brain irradiation by HER2 status. 
Figure 4 Overall survival after repeat brain irradiation by HER2
status, 37 patients.
Table 4 Univariate analysis of potential prognostic
factors at repeat brain irradiation
Variables p value (log-rank test)
RPA at re-BRT < 0.001
Craniotomy at initial BM 0.18
Craniotomy at re-BRT 0.99
Number of BM at re-BRT 0.001
HER2 status 0.66
Trastuzumab on or after BM* 0.12
Chemotherapy on or after BM* 0.33
ER status 0.87
Tumour grade < 0.001
* Refers to treatments given on or after the date of brain re-irradiation.
Abbreviations: re-BRT = repeat brain irradiation, RPA = recursive partitioning
analysis, HER2 = human epidermal growth factor receptor 2, BM = brain
metastasis, ER = estrogen receptor
 
Overall survival after repeat brain irradiation by RPA class.
Figure 5 Overall survival after repeat brain irradiation by RPA
class, 37 patients.
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Page 7 of 8Conclusion
Within the constraints of a retrospective review, this
contemporary population-based study showed that the
median survival after initial BRT for patients with breast
cancer was 4.5 months and that, as demonstrated in
previous studies, RPA class was prognostically impor-
tant. Among those treated with repeat BRT, there was a
higher proportion of cases with HER2 positive disease
compared to HER2 negative disease. Patients with RPA
class 1 and 2 should be strongly considered for brain re-
irradiation.
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